D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.
TL;DR: The background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation are summarized.
Journal ArticleDOI
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors.
Carlos Becerra,Jeffrey R. Infante,Lawrence E. Garbo,Michael S. Gordon,David Smith,Fadi Braiteh,David R. Gandara,Robert M. Jotte,Karen L. Reckamp,Filip Janku,Howard A. Burris,Kevin M. Bellew,Olivia Gardner,Li Liu,Donna S. Cox,Vijay Gopal Reddy Peddareddigari,George R. Blumenschein +16 more
TL;DR: This is a two-part, five-arm, phase I/Ib, open-label study to evaluate the safety and tolerability of trametinib plus doc, erl, pem, pEM+carboplatin (pem+carbo), or nab-paclitaxel (nab-pac) (NCT01192165).
Journal ArticleDOI
Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403).
Philip C. Mack,Jieling Miao,Mary W. Redman,James Monk,J. Goldberg,Roy S. Herbst,Mary Ann Melnick,Zenta Walther,Fred R. Hirsch,Katerina Politi,Karen Kelly,David R. Gandara +11 more
TL;DR: Plasma clearance of mutant EGFR ctDNA at 8-weeks was highly and significantly predictive of progression-free and overall survival, outperforming RECIST response for predicting long-term benefit.
Journal ArticleDOI
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
Nele Van Der Steen,Nele Van Der Steen,Yves Mentens,M. Ramael,Leticia G. Leon,Paul Germonpré,Jose Ferri,David R. Gandara,Elisa Giovannetti,Elisa Giovannetti,Godefridus J. Peters,Patrick Pauwels,Christian Rolfo +12 more
TL;DR: An overview of patients with intrinsic double mutations in oncogenic drivers and their reported response to targeted therapies, with a focus on epidermal growth factor receptor, anaplastic lymphoma kinase, cMET, and Kirsten rat sarcoma viral oncogene is provided.
Journal ArticleDOI
Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
Harsha Ranganath,Amit B. Jain,Justine R. Smith,Julie Ryder,Amina Chaudry,Emily Miller,Felicia Hare,Poojitha Valasareddy,Robert S. Seitz,David R. Hout,Matthew G. Varga,Brock L. Schweitzer,Tyler J. Nielsen,Janice Nhan Mullins,Douglas T. Ross,David R. Gandara,Gregory A. Vidal +16 more
TL;DR: In this article , a 27-gene RT-qPCR immuno-oncology (IO) gene expression assay of the tumor immune microenvironment was evaluated in 67 advanced-stage NSCLC patients.